Liver Cancer Treatment in India 2026: TACE, Y90, Resection, Transplant Eligibility & Costs
Liver Cancer Treatment in India 2026: TACE, Y90, Liver Resection, Transplant and Costs
Liver cancer — predominantly hepatocellular carcinoma (HCC) — carries a devastating burden across Africa. Sub-Saharan Africa has the world's highest liver cancer incidence rates, driven by endemic Hepatitis B virus (HBV) infection that affects 8–15% of the adult population in many countries, combined with aflatoxin exposure from contaminated food and, increasingly, Hepatitis C (HCV) infection.
By the time liver cancer is diagnosed in many African patients, it has often progressed beyond what local services can treat. Yet India's interventional oncology, hepatology surgery, and transplant programmes offer treatment options across all disease stages — from locoregional therapies for intermediate-stage disease to surgical resection and liver transplant for eligible patients.
TL;DR: TACE (locoregional treatment) in India costs USD 4,000–7,000 per session. Y90 radioembolization costs USD 12,000–20,000. Liver resection costs USD 8,000–15,000. Living donor liver transplant (LDLT) for HCC costs USD 35,000–55,000. All significantly below Western equivalents.
Understanding HCC Staging
Treatment decisions in HCC depend on the staging system used. The Barcelona Clinic Liver Cancer (BCLC) system is most widely used internationally:
- BCLC Stage 0/A (very early/early): Single tumour ≤5 cm or up to 3 nodules ≤3 cm, preserved liver function (Child-Pugh A/B), no vascular invasion. Candidates for curative treatment: resection or transplant.
- BCLC Stage B (intermediate): Large, multifocal HCC, no vascular invasion or metastasis. Best treated with TACE.
- BCLC Stage C (advanced): Portal vein involvement or limited extrahepatic spread. Candidates for systemic therapy ± Y90.
- BCLC Stage D (terminal): Severe liver dysfunction. Supportive care focus.
Most African patients arrive in India at Stage B or C due to delayed diagnosis. India's interventional teams are experienced in treating these stages with locoregional therapies.
The Hepatitis B and C Context for African Patients
The relationship between viral hepatitis and liver cancer is critical for African patients.
Hepatitis B (HBV): Chronic HBV infection causes 60–70% of liver cancers in Africa. In India, HCC on HBV background is extremely common — Indian hepatologists and oncologists are highly experienced managing this. On arrival, your antiviral therapy (tenofovir, entecavir) should be reviewed, optimised, and continued throughout cancer treatment.
Hepatitis C (HCV): HCV-related HCC is increasing in Africa. India has access to highly effective direct-acting antiviral (DAA) regimens (sofosbuvir-based) at dramatically affordable prices — generic DAAs in India cost USD 100–400 for a curative 12-week course compared to USD 20,000–80,000 in Western markets. Treating HCV before or alongside HCC treatment improves overall outcomes.
At Indian centres, hepatology and oncology teams work together — HCC treatment does not proceed in isolation from underlying liver disease management.
Locoregional Treatments
TACE (Transarterial Chemoembolization)
TACE is the standard treatment for intermediate-stage HCC (BCLC B) and is also used for downstaging — reducing tumour size to bring patients within transplant criteria.
The procedure:
- An interventional radiologist (IR) threads a catheter through the femoral or radial artery to the hepatic artery branches feeding the tumour
- Chemotherapy (typically doxorubicin or cisplatin) is injected directly into the tumour vasculature
- Embolic particles are deployed to cut off the tumour's blood supply, trapping chemotherapy in situ
- The tumour receives concentrated chemotherapy while systemic exposure is minimised
TACE is performed under conscious sedation or light general anaesthesia. Hospital stay: 1–3 nights for observation. Recovery: 1–2 weeks of fatigue and post-embolization syndrome (fever, pain) before returning to baseline.
Costs in India: USD 4,000–7,000 per session (conventional TACE) or USD 5,000–8,500 (drug-eluting bead TACE, DEB-TACE). Most patients require 1–3 sessions over several months.
Y90 Radioembolization (SIRT)
Y90 radioembolization delivers Yttrium-90 loaded microspheres via the hepatic artery, delivering targeted internal radiation directly to tumour tissue. It is particularly effective for:
- HCC with portal vein involvement (where TACE is contraindicated)
- Large right lobe HCC
- Patients needing liver lobe downstaging before resection
- As an alternative to TACE in certain anatomical situations
The procedure requires pre-treatment mapping (MAA scan to assess lung shunt fraction) before the actual treatment session. Total India stay for Y90: approximately 7–10 days including mapping and treatment.
Costs in India: USD 12,000–20,000 per session. In the USA: USD 30,000–55,000+. Available at Apollo Hospitals (multiple centres), Tata Medical Centre, and select Fortis and Max hospitals.
Ablation (RFA and MWA)
Radiofrequency ablation (RFA) and microwave ablation (MWA) destroy small tumours (≤3 cm) directly using heat delivered via a needle under CT or ultrasound guidance. These are day procedures with 1 overnight stay.
Costs: USD 2,500–5,000 per session. Excellent outcomes for small HCC in patients not suitable for surgery.
Surgical Resection
For early-stage HCC (single tumour, no vascular invasion, adequate residual liver function), surgical resection offers potentially curative treatment with 5-year survival rates of 40–70% in well-selected patients.
Key considerations:
- Future liver remnant (FLR): Enough functional liver must remain after resection. Portal vein embolization (PVE) can be performed pre-operatively to induce hypertrophy of the future remnant.
- Background liver disease: Cirrhosis (common in HBV/HCV patients) limits resection margins. Patients with preserved Child-Pugh A function tolerate resection best.
Laparoscopic liver resection is available at high-volume centres in India, reducing recovery time compared to open surgery.
Costs: Open liver resection USD 8,000–15,000. Laparoscopic resection USD 10,000–18,000. ICU stay included.
Liver Transplant for HCC
Liver transplant offers the best chance of cure for HCC within Milan Criteria, as it removes both the tumour and the diseased liver driving new tumour formation.
Milan Criteria for transplant eligibility: Single tumour ≤5 cm, or up to 3 nodules each ≤3 cm, no macrovascular invasion, no extrahepatic disease.
Extended criteria (UCSF, AFP-based models): Select centres use expanded criteria — Arodya will clarify your eligibility at the specific centre being considered.
Living Donor Liver Transplant (LDLT): India's transplant programme is predominantly LDLT — a family member donates a liver lobe. This avoids the long wait for deceased donor organs. The donor must be 18–55 years, blood-group compatible, BMI <30, medically fit, and willing. Costs: USD 35,000–55,000 all-in for recipient, with the donor's surgery and care included.
LDLT for HCC in India is available at Apollo (Chennai, Delhi), Fortis Gurugram, Medanta, Max Saket, and ILBS Delhi. For a comparison of these hospitals, see our Apollo, Fortis, Max, and Medanta Delhi comparison guide.
Systemic Therapy
For advanced HCC (BCLC C), systemic therapy is the primary treatment modality. India offers:
- Sorafenib: Standard first-line targeted therapy. Generic available in India at USD 200–400/month vs USD 8,000+/month in the USA.
- Lenvatinib: Alternative first-line option. Generic available in India.
- Atezolizumab + Bevacizumab (Tecentriq + Avastin): Immunotherapy combination now first-line for well-preserved liver function HCC. Biosimilar bevacizumab available in India significantly reduces cost. Course costs USD 3,000–8,000/month vs USD 20,000+/month in the USA.
- Regorafenib, cabozantinib: Second-line options, generics available in India.
For a broader understanding of cancer drug costs in India, see our chemotherapy cost guide.
Planning Your Liver Cancer Treatment in India
African patients planning liver cancer treatment in India should prepare:
- All imaging: CT liver (triphasic protocol), MRI liver, chest CT for staging
- HBV/HCV status and viral load
- Liver function tests (Child-Pugh score) and AFP
- Biopsy results if available (not always mandatory for diagnosis if imaging meets radiological criteria)
- Current medications and any previous treatment
A telemedicine consultation with an Indian hepato-oncologist or interventional radiologist can confirm treatment eligibility and options before you travel. India's best centres have multidisciplinary tumour boards — your case will be reviewed by hepatology, oncology, interventional radiology, and surgery together.
When you are ready to move forward, start your inquiry here. Liver cancer on a background of Hepatitis B is a condition India's teams treat every day for African patients — and the treatment options available here are genuinely transformative compared to what is accessible at home.
